Tevogen Bio Holdings Inc.
FRC CoverageTevogen Bio Holdings Inc.
FRC CoverageYour view on TVGN
Overview
What the company does, where it operates, and who runs it.
*Tevogen Bio Holdings Inc. has paid FRC a fee for research coverage and distribution of reports.
About Tevogen Bio Holdings Inc.
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ryan H. Saadi M.P.H,
- Headquarters
- 15 Independence Boulevard Suite #410, Warren, NJ, US
- Industry
- Biotechnology
- Sector
- Healthcare
- CEO
- Ryan H. Saadi M.P.H,
- Headquarters
- 15 Independence Boulevard Suite #410, Warren, NJ, US
Tevogen Bio Holdings Inc., a clinical-stage specialty immunotherapy company, develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and other disorders.
The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment of ambulatory high-risk adult COVID-19 patients; and in phase 1 clinical trial to treat acute SARS-CoV-2 patients with B-cell cancer immune suppression, and other B cell immune suppressed acute SARS-CoV-2 patients with a B cell cancer indication, as well as Long COVID prevention and treatment.
Fast Tracking a Potential Breakthrough for Treating Viral Infections and Cancer
Sign in to view
Fast Tracking a Potential Breakthrough for Treating Viral Infections and Cancer
Sign in to view
Research Reports
FRC analyst coverage and recommendations.
Past Reports
Historical coverage archive.
Analyst Notes
Ongoing commentary and updates from FRC analysts.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Tevogen Bio Holdings Inc., and the rating behind it. TVGN last traded at $7.36; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Tevogen Bio Holdings Inc.. Starting points for Tevogen Bio Holdings Inc.: EPS -$5.64, beta 0.20 — an Biotechnology name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Tevogen Bio Holdings Inc.. Tevogen Bio Holdings Inc. does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Tevogen Bio Holdings Inc.. Trailing twelve-month EPS for Tevogen Bio Holdings Inc. stands at -$5.64. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Tevogen Bio Holdings Inc.. Tevogen Bio Holdings Inc. has reported as a listed company since 2022. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Tevogen Bio Holdings Inc. valued side by side against its closest peers. Tevogen Bio Holdings Inc. is measured against Biotechnology peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Tevogen Bio Holdings Inc., and how their positions are changing. At a $30.6M market value, institutional positions materially move Tevogen Bio Holdings Inc.'s register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Tevogen Bio Holdings Inc. executives and directors. Shares of Tevogen Bio Holdings Inc. have traded between $0.38 and $1.92 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Tevogen Bio Holdings Inc.. Tevogen Bio Holdings Inc. is a $30.6M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Tevogen Bio Holdings Inc.. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Tevogen Bio Holdings Inc.. Coverage tracks Tevogen Bio Holdings Inc. within Biotechnology (Healthcare). Press releases and market coverage, newest first.
